Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04458909
Recruitment Status : Suspended (Other - reassessing due to 6/2021 ASCO data)
First Posted : July 7, 2020
Last Update Posted : July 28, 2021
Sponsor:
Collaborator:
NRG Oncology
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : May 9, 2028
Estimated Study Completion Date : May 9, 2028